Professional Background:
Dr. Brad Walsh is Chief Executive Officer and Managing Director of GlyTherix Ltd, a Sydney-based biotechnology company specialising in immuno-oncology. He founded GlyTherix to bring to market an innovative antibody for treatment of solid tumours from cancers such as prostate, glioblastoma, bladder, pancreas, lung, mesothelioma, ovarian and esophageal. Dr Walsh has led the company’s scientific and business development, raising capital to bring the company to successful completion of a First-in-Human safety study of Miltuximab®, its lead compound. The company is currently planning a Phase1 trial to be conducted in Australia.
Research Interests:
Dr. Walsh’s career in biotechnology began with a PhD in protein chemistry. Over the following years he led research groups in government agencies, universities and hospitals and was a key part of the establishment of a major national research facility, APAF. He continues to be active in research collaborations and academic supervision and was a joint recipient of one of Australia’s most prestigious awards, a Eureka Prize, for Interdisciplinary Research in 2015. He has co-authored over 125 peer reviewed papers and book chapters and nine patents. He is a strong supporter of internship opportunities for students, serving as an Industry Mentoring Network in STEM mentor since 2017.
